Volume 28, Number 2—February 2022
Research
Comparison of Complications after Coronavirus Disease and Seasonal Influenza, South Korea
Table 3
Factors associated with incidence of complications in study of COVID-19 and influenza patients, South Korea*
Variable | Adjusted odds ratio (95% CI)† |
|
---|---|---|
COVID-19, n = 21,615 | Influenza, n = 2,380,696 | |
Female (referent: male) |
1.03 (0.96–1.11) |
1.04 (1.04–1.05) |
Age, y (referent: 20–44 y) | ||
0–19 | 0.69 (0.59–0.80) | 0.94 (0.94–0.95) |
45–64 | 0.81 (0.74–0.88) | 0.97 (0.96–0.98) |
65–74 | 0.86 (0.76–0.96) | 1.07 (1.05–1.08) |
>75 |
0.86 (0.75–0.99) |
1.26 (1.24–1.28) |
National Health Insurance Service (referent: Medical Aid) |
0.85 (0.75–0.97) |
0.94 (0.92–0.96) |
Region (referent: other areas) | ||
Seoul metropolitan area | 0.90 (0.82–0.99) | 1.03 (1.02–1.03) |
Daegu and Gyeongsangbuk province |
1.44 (1.31–1.59) |
1.02 (1.01–1.03) |
Charlson Comorbidity Index score (referent: 0) | ||
1–2 | 1.02 (0.94–1.11) | 1.08 (1.08–1.09) |
>3 |
1.01 (0.88–1.16) |
1.12 (1.10–1.13) |
Severity (referent ambulatory state) | ||
Hospitalized mild disease | 1.19 (1.09–1.30) | 1.22 (1.21–1.23) |
Hospitalized severe disease | 1.11 (0.91–1.34) | 1.36 (1.29–1.43) |
*COVID-19, coronavirus disease. †Multivariable logistic regression includes sex, age, type of insurance, region, and Charlson Comorbidity Index.
1These first authors contributed equally to this article.
2These corresponding authors contributed equally to this article.